Original Source(s)
Related Content
Oral Aleniglipron Reduced Weight at 36 Weeks
In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.
July 16, 2026
-
6 min
Serostatus May Modify RA Activity–CV Link
Combined rheumatoid factor and anticitrullinated protein antibody status appeared to modify the association between baseline rheumatoid arthritis disease activity and subsequent cardiovascular events in an international observational cohort.
July 15, 2026
-
4 min
Oral Shigella Vaccine Hits 89% Efficacy in Challenge Trial
An investigational oral Shigella sonnei vaccine showed robust protection against shigellosis in a phase 2 controlled human infection trial.
by Teraya Smith
July 23, 2026
-
3 min
